NEW YORK (GenomeWeb News) – BG Medicine today announced a public offering of its stock that it expects to bring in $11.1 million in net proceeds.

The cardiovascular diagnostics firm also announced a common stock purchase agreement for up to $12 million, as well as preliminary financials for the fourth quarter and full-year ended Dec. 31, 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.